Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This is a phase II, multicenter, randomised, parallel, double-blind, placebo-controlled study assessing the efficacy and safety of the MEKi selumetinib compared with placebo in Chinese paediatric participants with post-operative NF1-associated PNs.
Epistemonikos ID: 3d13100f7750c7a527289ac7dfa6d284460b51dc
First added on: Feb 19, 2024